Literature DB >> 28638729

Cellular immunotherapies for cancer.

Pedro Berraondo1,2,3, Sara Labiano1,2, Luna Minute1,2, Iñaki Etxeberria1,2, Marcos Vasquez1,2, Alvaro Sanchez-Arraez1,2, Alvaro Teijeira1,2,3, Ignacio Melero1,2,3,4.   

Abstract

Lessons learned over decades on the use of gene and cell therapies have found clinical applicability in the field of cancer immunotherapy. On December 16th, 2016 a symposium was held in Pamplona (Spain) to analyze and discuss the critical points for the clinical success of adoptive cell transfer strategies in cancer immunotherapy. Cellular immunotherapy is being currently exploited for the development of new cancer vaccines using ex vivo manipulated dendritic cells or to enhance the number of effector cells, transferring reinvigorated NK cells or T cells. In this meeting report, we summarize the main topics covered and provide an overview of the field of cellular immunotherapy.

Entities:  

Keywords:  Chimeric antigen receptor; NK cells; Tumor-infiltrating lymphocytes; dendritic cells

Year:  2017        PMID： 28638729      PMCID： PMC5467985          DOI： 10.1080/2162402X.2017.1306619

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  31 in total

1.  Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.

Authors:  L Fernández; J Valentín; M Zalacain; W Leung; A Patiño-García; A Pérez-Martínez
Journal:  Cancer Lett       Date:  2015-08-11       Impact factor: 8.679

2.  Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation.

Authors:  Antonio Perez-Martinez; Rekha Iyengar; Kwan Gan; Thirachit Chotsampancharoen; Barbara Rooney; Marti Holladay; Manuel Ramírez; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

3.  An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/target cell synapse.

Authors:  Florie Bertrand; Sabina Müller; Kyung-Ho Roh; Camille Laurent; Loïc Dupré; Salvatore Valitutti
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

4.  Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

Authors:  Ghaith Bakdash; Sonja I Buschow; Mark A J Gorris; Altuna Halilovic; Stanleyson V Hato; Annette E Sköld; Gerty Schreibelt; Simone P Sittig; Ruurd Torensma; Tjitske Duiveman-de Boer; Christoph Schröder; Evelien L Smits; Carl G Figdor; I Jolanda M de Vries
Journal:  Cancer Res       Date:  2016-06-20       Impact factor: 12.701

5.  Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.

Authors:  Manja Idorn; Per Thor Straten; Inge Marie Svane; Özcan Met
Journal:  Methods Mol Biol       Date:  2016

6.  Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation.

Authors:  Rodrigo Hess Michelini; Teresa Manzo; Tabea Sturmheit; Veronica Basso; Martina Rocchi; Massimo Freschi; Joanna Listopad; Thomas Blankenstein; Matteo Bellone; Anna Mondino
Journal:  Cancer Res       Date:  2013-06-07       Impact factor: 12.701

7.  Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo.

Authors:  Antonio Pérez-Martínez; Jaime Valentín; Lucía Fernández; Enrique Hernández-Jiménez; Eduardo López-Collazo; Petra Zerbes; Ellen Schwörer; Fernando Nuñéz; Inmaculada Génesis Martín; Hannah Sallis; Miguel Ángel Díaz; Rupert Handgretinger; Matthias Manuel Pfeiffer
Journal:  Cytotherapy       Date:  2014-12-23       Impact factor: 5.414

Review 8.  Adoptive T-cell therapy for cancer: The era of engineered T cells.

Authors:  Chiara Bonini; Anna Mondino
Journal:  Eur J Immunol       Date:  2015-08-21       Impact factor: 5.532

9.  Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.

Authors:  Erik H J G Aarntzen; Mangala Srinivas; Fernando Bonetto; Luis J Cruz; Pauline Verdijk; Gerty Schreibelt; Mandy van de Rakt; W Joost Lesterhuis; Maichel van Riel; Cornelius J A Punt; Gosse J Adema; Arend Heerschap; Carl G Figdor; Wim J Oyen; I Jolanda M de Vries
Journal:  Clin Cancer Res       Date:  2013-02-04       Impact factor: 12.531

10.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245
View more
  9 in total

1.  Imaging activated T cells predicts response to cancer vaccines.

Authors:  Israt S Alam; Aaron T Mayer; Idit Sagiv-Barfi; Kezheng Wang; Ophir Vermesh; Debra K Czerwinski; Emily M Johnson; Michelle L James; Ronald Levy; Sanjiv S Gambhir
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 2.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 3.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

4.  In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Authors:  O Adotevi; Y Godet; J Galaine; Z Lakkis; I Idirene; J M Certoux; M Jary; R Loyon; C Laheurte; S Kim; A Dormoy; F Pouthier; C Barisien; F Fein; P Tiberghien; X Pivot; S Valmary-Degano; C Ferrand; P Morel; E Delabrousse; C Borg
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

5.  4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12.

Authors:  Marcelo M Rodríguez; Esteban Fiore; Juan Bayo; Catalina Atorrasagasti; Mariana García; Agostina Onorato; Luciana Domínguez; Mariana Malvicini; Guillermo Mazzolini
Journal:  Mol Ther       Date:  2018-09-18       Impact factor: 11.454

Review 6.  Disease-Associated Plasmacytoid Dendritic Cells.

Authors:  Shuang Li; Jing Wu; Shan Zhu; Yong-Jun Liu; Jingtao Chen
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

Review 7.  Trial watch: Peptide-based vaccines in anticancer therapy.

Authors:  Lucillia Bezu; Oliver Kepp; Giulia Cerrato; Jonathan Pol; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

Review 8.  Bioengineering tools for probing intracellular events in T lymphocytes.

Authors:  Xinyuan Zhang; Chelsea F Mariano; Yuta Ando; Keyue Shen
Journal:  WIREs Mech Dis       Date:  2020-10-19

9.  Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.

Authors:  He Li; Yao Huang; Du-Qing Jiang; Lian-Zhen Cui; Zhou He; Chao Wang; Zhi-Wei Zhang; Hai-Li Zhu; Yong-Mei Ding; Lin-Fang Li; Qiang Li; Hua-Jun Jin; Qi-Jun Qian
Journal:  Cell Death Dis       Date:  2018-02-07       Impact factor: 8.469
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.